Buprenorphine / Naloxone Uses, Dosage, Side Effects and Interactions
Suboxone
Suboxone was the first buprenorphine / naloxone product the FDA approved, in October 2002. An FDA-approved generic with the same active ingredients is listed.
Zubsolv
Zubsolv came 10 years after Suboxone (July 2013) as a sublingual tablet. The FDA rates no generic as a substitute for it.
Bunavail
Bunavail came 11 years after Suboxone (June 2014) as a buccal film, a form not listed for Suboxone. The FDA now lists it as discontinued; generic buprenorphine / naloxone is still listed.
Buprenorphine / Naloxone is a combination medicine placed under the tongue (or, for the film, inside the cheek) to treat opioid dependence, as part of a full treatment plan with counseling.
Quick links
Ask Anything About Buprenorphine / NaloxoneType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Buprenorphine / Naloxone in Short
- Drug classes Opioid Antagonist; Partial Opioid Agonist How the FDA classifies it
What it treatsBuprenorphine / Naloxone treats opioid dependence. It should always be used as part of a complete treatment plan that includes counseling and psychosocial support. The sublingual tablet labels describe it as maintenance treatment of opioid dependence.
- How you get it Prescription only Controlled substance, Schedule III
- Comes asSublingual tablet and sublingual filmAvailable strengths (buprenorphine/naloxone)
Sublingual tablet (under the tongue)
- 0.7 mg/0.18 mg
- 1.4 mg/0.36 mg
- 2 mg/0.5 mg
- 2.9 mg/0.71 mg
- 5.7 mg/1.4 mg
- 8 mg/2 mg
See forms and strengths+ 6 more strengthsShow fewer strengths
Sublingual tablet (under the tongue)
- 8.6 mg/2.1 mg
- 11.4 mg/2.9 mg
Sublingual film (inside the cheek, under the tongue)
- 2 mg/0.5 mg
- 4 mg/1 mg
- 8 mg/2 mg
- 12 mg/3 mg
- Crushing or chewingSome forms are on our Do Not Crush list Listed: Buprenorphine hydrochloride-naloxone hydrochloride (tablet, sublingual); Zubsolv (tablet, sublingual)
- Important safety informationWarnings and precautions Read the warnings and precautions for your exact product.
- What pharmacies pay
- Generic$0.54 to $0.74 a tablet
- Zubsolv (brand)$5.26 to $21.04 a tablet
- Sublingual films, generic: $1.33 to $4.13 each
The pharmacy’s own cost, national average. Not your price See every price+ 1 more price detailShow fewer price details
- Sublingual films, Suboxone: $4.78 to $17.16 each
- Generic versionYes, FDA-approved Listed with the FDA, which does not mean every pharmacy stocks it
- Generic launchSeptember 2030 Our estimate for the first generic of Zubsolv
The Pharmacist’s Take
Buprenorphine / naloxone (Suboxone and others) is a widely used first-line treatment for opioid dependence that pairs buprenorphine, which only partly switches on opioid receptors to ease withdrawal and cravings, with naloxone, which does little under the tongue but discourages injecting it; it is meant to be used with counseling, has been on the U.S. market since about 2010, and has FDA-approved generics listed. Most people tolerate it well once the dose is settled, and headache, nausea, constipation, sweating and trouble sleeping are what people usually notice. The serious risk is slowed, shallow breathing, especially when it is mixed with alcohol, benzodiazepines or other sedating drugs.
Key Takeaways From the HelloPharmacist Team
- Let each dose dissolve fully under your tongue, or the film inside your cheek, as a single daily dose.
- Hold your first dose until clear withdrawal symptoms have started, as your prescriber directs, since dosing too early can bring on sudden withdrawal.
- Lock it away from children and keep naloxone, the overdose rescue medicine, at home, calling 911 even after giving it.
- Do not stop it suddenly, since withdrawal can follow; your prescriber will taper the dose gradually when the time comes.
Patient Information Guide for Buprenorphine / Naloxone
What It’s Used For
Buprenorphine / Naloxone treats opioid dependence, always alongside counseling and psychosocial support.
- Buprenorphine and naloxone sublingual tablets: maintenance treatment of opioid dependence.
- Buprenorphine and naloxone sublingual film (including Suboxone film, used sublingually or buccally): treatment of opioid dependence.
- Zubsolv (orally disintegrating sublingual tablet): treatment of opioid dependence.
How It Works
Buprenorphine partially activates the mu-opioid receptor and blocks the kappa-opioid receptor. This eases withdrawal while limiting the full effects of stronger opioids. Naloxone is a strong opioid blocker. It does little when the medicine is taken under the tongue, but it can bring on withdrawal if the product is injected by someone dependent on full opioids.
Drug Class
Drug Class
- Partial Opioid Agonist from buprenorphine
- Opioid Antagonist from naloxone
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class. Buprenorphine / Naloxone has two active ingredients, so each class says which one it comes from.
Drug Class
Established Pharmacologic Class (EPC)- Partial Opioid Agonist from buprenorphine
- Opioid Antagonist from naloxone
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)- Partial Opioid Agonists from buprenorphine
- Opioid Antagonists from naloxone
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)None listed for Buprenorphine / Naloxone in the FDA’s index.
From our Patient Information GuideBuprenorphine partially activates the mu-opioid receptor and blocks the kappa-opioid receptor. This eases withdrawal while limiting the full effects of stronger opioids. Naloxone is a strong opioid blocker. Read How Buprenorphine / Naloxone Works
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)None listed for Buprenorphine / Naloxone in the FDA’s index.
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- Oripavine derivatives from buprenorphine
- Drugs used in opioid dependence from buprenorphine
- Peripheral opioid receptor antagonists from naloxone
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Dosage
This medicine is taken once a day, under the tongue. The film can also be used inside the cheek.
- Treatment is started when clear withdrawal signs are present, to avoid triggering withdrawal.
- The film and Zubsolv are given in divided doses at the start of treatment.
- Your dose is then adjusted to keep you in treatment and control withdrawal symptoms.
- Follow your prescriber and the label for your exact instructions.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Buprenorphine / Naloxone Sublingual Tablets
Opioid dependence
Adults · Maintenance dose Dose 4/1 mg Highest dose 24/6 mg
Step by step
- Generally in the range of 4 mg/1 mg buprenorphine/naloxone to 24 mg/6 mg buprenorphine/naloxone per day, as a single daily dose
- Adjusted in increments/decrements of 2 mg/0.5 mg or 4 mg/1 mg
- Dosages higher than 24 mg/6 mg have not been demonstrated to provide any clinical advantage
Adults · Target dose Usual dose 16 mg/4 mg once a day
- 16 mg/4 mg buprenorphine/naloxone/day as a single daily dose
Adults dependent on short-acting opioids such as heroin · Zubsolv 5.7 mg/1.4 mg Starting dose 1.4 mg/0.36 mg Highest dose 5.7 mg/1.4 mg on Day 1
- Start with 1.4 mg/0.36 mg, then remainder of up to 4.2 mg/1.08 mg in doses of 1 to 2 tablets of 1.4 mg/0.36 mg at 1.5 to 2 hour intervals
Good to know
Some patients may tolerate up to 3 x 1.4 mg/0.36 mg as a single, second dose
Zubsolv is a brand name for this medicine. See Zubsolv’s full dosing instructions on DailyMed →
Adults dependent on short-acting opioids such as heroin · Zubsolv 11.4 mg/2.9 mg Highest dose 11.4 mg/2.9 mg once a day
- A single daily dose of up to 11.4 mg/2.9 mg
Zubsolv is a brand name for this medicine. See Zubsolv’s full dosing instructions on DailyMed →
Adults · Zubsolv 2.9 mg/0.71 mg Dose 2.9/0.71 mg
- Generally in the range of 2.9 mg/0.71 mg to 17.2 mg/4.2 mg per day, based on clinical response
Zubsolv is a brand name for this medicine. See Zubsolv’s full dosing instructions on DailyMed →
Suboxone
Opioid dependence
Adults dependent on short-acting opioids such as heroin · Day 1 Starting dose 2 mg/0.5 mg or 4 mg/1 mg Highest dose 8 mg/2 mg on Day 1
- Up to 8 mg/2 mg buprenorphine and naloxone sublingual film, starting with 2 mg/0.5 mg or 4 mg/1 mg and titrating upwards in 2 or 4 mg increments of buprenorphine at approximately 2-hour intervals
Adults dependent on short-acting opioids such as heroin · Day 2 Highest dose 16 mg/4 mg once a day
- A single daily dose of up to 16 mg/4 mg buprenorphine and naloxone sublingual film
Adults · Maintenance dose Dose 4/1 mg
- Generally in the range of 4 mg/1 mg to 24 mg/6 mg per day, based on clinical response, as a single daily dose
What a maintenance dose is: The regular ongoing dose taken to keep a steady, effective amount of medicine in the body over time.
Side Effects
Common side effects seen with this medicine include:
Common side effects
- Headache
- Nausea and vomiting
- Constipation
- Sweating
- Trouble sleeping (insomnia)
- Pain
- Withdrawal symptoms
- Numbness, redness or soreness in the mouth or tongue
- Swelling in the hands or feet
When to get medical help
- Call 911 or get emergency help right away for a known or suspected overdose, such as very slow or shallow breathing, extreme sleepiness or pinpoint pupils.
- Get help right away for signs of a severe allergic reaction, such as hives, swelling, wheezing or trouble breathing.
- Call your doctor if you have yellowing of the skin or eyes, dark urine or other signs of liver problems.
- Call your doctor if you have nausea, vomiting, loss of appetite, severe tiredness, weakness, dizziness or low blood pressure, which can be signs of adrenal insufficiency.
- Seek help for signs of serotonin syndrome if you take other serotonin-affecting drugs.
- Tell your dentist or doctor about dental problems such as tooth decay, broken teeth or tooth loss.
Warnings and Precautions
- Breathing problems: Life-threatening slowed breathing and death can occur, especially with alcohol, benzodiazepines or other sedating drugs, or injection misuse.
- Misuse: It can be abused like other opioids. Keep it secure.
- Children: Accidental exposure can cause severe, possibly fatal, breathing problems.
- Liver: Hepatitis and liver events have been reported. Liver tests are recommended.
- Withdrawal: Stopping suddenly can cause withdrawal, so the dose is tapered gradually.
- Adrenal insufficiency: Reported with opioids, more often after over a month of use.
- Allergic reactions: Rash, hives, swelling and anaphylaxis have been reported.
Interactions
Several types of medicines can clash with this one:
- Alcohol, benzodiazepines and other sedating drugs: dangerous breathing slowdown, coma and death.
- CYP3A4 inhibitors (erythromycin, ketoconazole, ritonavir): raise buprenorphine levels.
- CYP3A4 inducers (rifampin, carbamazepine, phenytoin): lower levels and may cause withdrawal.
- Some HIV medicines (efavirenz, nevirapine, etravirine, delavirdine, atazanavir): may need dose monitoring.
- Serotonin-affecting drugs: risk of serotonin syndrome.
- MAO inhibitors: not recommended during use or within 14 days of stopping.
- Muscle relaxants: greater breathing depression.
- Diuretics: may work less well.
- Anticholinergic drugs: urinary retention and severe constipation.
Interactions Listed in the FDA-Approved Label
From the Buprenorphine / Naloxone prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
Benzodiazepines and other CNS depressants For example: alcoholWhat happensAdditive effects increase the risk of respiratory depression, profound sedation, coma, and death.What to doCessation of benzodiazepines or other CNS depressants is preferred in most cases; if concomitant use is warranted, strongly consider recommending or prescribing an opioid overdose reversal agent.
-
CYP3A4 inhibitors For example: erythromycin, ketoconazole, ritonavirWhat happensCan increase buprenorphine plasma concentration, resulting in increased or prolonged opioid effects.What to doConsider dosage reduction until stable drug effects are achieved and monitor for respiratory depression and sedation; if the inhibitor is stopped, consider increasing the dosage and monitor for withdrawal.
-
CYP3A4 inducers For example: rifampin, carbamazepine, phenytoinWhat happensCan decrease buprenorphine plasma concentration, potentially causing decreased efficacy or withdrawal syndrome.What to doConsider increasing the dosage until stable drug effects are achieved and monitor for withdrawal; if the inducer is stopped, consider dosage reduction and monitor for respiratory depression.
-
Antiretrovirals: NNRTIs (efavirenz, nevirapine, etravirine, delavirdine)What happensSignificant pharmacokinetic interactions have been shown, but did not result in significant pharmacodynamic effects.What to doMonitor the dose if NNRTIs are added to chronic buprenorphine and naloxone treatment.
-
Antiretrovirals: protease inhibitors (atazanavir, ritonavir)What happensAtazanavir with or without ritonavir raised buprenorphine levels and caused increased sedation and symptoms of opioid excess; other PIs had little effect.What to doMonitor patients and reduce the dose if warranted.
-
Antiretrovirals: NRTIsWhat happensThey do not appear to induce or inhibit the P450 enzyme pathway, so no interactions with buprenorphine are expected.What to doNone
-
Serotonergic drugs (SSRIs, SNRIs, TCAs, triptans, mirtazapine, trazodone, tramadol, MAO inhibitors)What happensConcomitant use with opioids has resulted in serotonin syndrome.What to doCarefully observe the patient, particularly at initiation and dose adjustment; discontinue if serotonin syndrome is suspected.
-
Monoamine oxidase inhibitors (MAOIs)What happensInteractions with opioids may manifest as serotonin syndrome or opioid toxicity.What to doUse is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.
-
Muscle relaxants (cyclobenzaprine, metaxalone)What happensBuprenorphine may enhance neuromuscular blocking action and increase respiratory depression.What to doMonitor for respiratory depression and decrease the dosage of either drug as necessary; strongly consider an opioid overdose reversal agent.
-
DiureticsWhat happensOpioids can reduce the efficacy of diuretics by inducing release of antidiuretic hormone.What to doMonitor for diminished diuresis and/or effects on blood pressure and increase the diuretic dosage as needed.
Read the label’s full interactions text
7 DRUG INTERACTIONS Table 4 includes clinically significant drug interactions with buprenorphine and naloxone sublingual film. Table 4. Clinically Significant Drug Interactions Benzodiazepines and Other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effects, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death. Intervention: Cessation of benzodiazepines or other CNS depressants is preferred in most cases of concomitant use. In some cases, monitoring in a higher level of care for taper may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate. Before co-prescribing benzodiazepines for anxiety or insomnia, ensure that patients are appropriately diagnosed and consider alternative medications and non-pharmacologic treatments. If concomitant use is warranted, strongly consider recommending or prescribing an opioid overdose reversal agent, as is recommended for all patients on buprenorphine treatment for opioid use disorder. Examples: Alcohol, benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids (gabapentin or pregabalin), and other opioids. Inhibitors of CYP3A4 Clinical Impact: The concomitant use of buprenorphine and CYP3A4 inhibitors can increase the plasma concentration of buprenorphine, resulting in increased or prolonged opioid effects, particularly when an inhibitor is added after a stable dose of buprenorphine and naloxone sublingual film is achieved.
Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Do not use if allergic to buprenorphine or naloxone.
- Tell your prescriber about lung or breathing problems.
- Tell your prescriber about liver disease or hepatitis. It is not recommended in severe liver impairment and may not suit moderate impairment.
- Tell your prescriber if you are pregnant. Newborns may have withdrawal (NOWS), which is treatable, and the dose may need adjusting during pregnancy.
- Buprenorphine passes into breast milk.
- Older adults should be monitored for sedation and slowed breathing.
- Keep it away from children.
Overdose
Overdose can cause pinpoint pupils, sedation, low blood pressure, low blood sugar, slowed breathing and death. Call 911 right away. Treatment focuses on supporting breathing, and an opioid overdose reversal agent may help, though higher or repeated doses may be needed and long monitoring is important.
Half-Life and How Your Body Processes It
Buprenorphine is about 96% protein bound and is broken down mainly by the CYP3A4 enzyme. It leaves the body through urine and feces. Its half-life is about 24 to 42 hours, and naloxone's is about 2 to 12 hours, based on the film. Film and tablet products can deliver different amounts, and Zubsolv differs from Suboxone tablets, so strengths are not directly interchangeable.
Storage
Store at 20° to 25°C (68° to 77°F). Store buprenorphine and naloxone sublingual film securely and dispose of properly .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Buprenorphine / Naloxone: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Buprenorphine / Naloxone — the kind of thing our pharmacy team would talk through with you at the counter.
What is this medicine for?
How do I take it?
Can I drink alcohol or take my anxiety or sleep medicine with it?
What side effects should I expect?
Should I keep naloxone at home?
Is it safe in pregnancy or around kids?
Is buprenorphine / naloxone available over the counter?
Is buprenorphine / naloxone a controlled substance?
When was buprenorphine / naloxone first available?
Who makes buprenorphine / naloxone?
What is the brand name of buprenorphine / naloxone?
What is the generic name of Suboxone?
What drug class is buprenorphine / naloxone?
Is there a generic version of buprenorphine / naloxone?
What strengths does buprenorphine / naloxone come in?
How much does buprenorphine / naloxone cost?
Where can I read the buprenorphine / naloxone prescribing information (package insert)?
Can you crush buprenorphine / naloxone?
Is buprenorphine / naloxone gluten free?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Buprenorphine / Naloxone
Skip the scrolling. Ask in your own words and get an answer from Buprenorphine / Naloxone’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Buprenorphine / Naloxone’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Buprenorphine / Naloxone on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, as soon as they can.Buprenorphine / Naloxone Forms and Strengths (How It Comes)
Buprenorphine / Naloxone comes in 2 dose forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Buprenorphine / Naloxone inactive ingredients by manufacturer.
Sublingual tablet
How this form is used
- Buprenorphine and naloxone sublingual tablets are used for maintenance treatment of opioid dependence, with counseling and psychosocial support.
- Zubsolv is used for treatment of opioid dependence, with counseling and psychosocial support.
- Buprenorphine and naloxone sublingual tablets are placed under the tongue as a single daily dose.
- Zubsolv is taken under the tongue as a single daily dose after induction, and is given in divided doses at the start of treatment.
- Zubsolv has different bioavailability from Suboxone tablets, so milligram strengths of different products are not directly comparable.
Show 6 more strengths Show fewer strengths
Sublingual film
How this form is used
- Suboxone sublingual film is used for treatment of opioid dependence, as part of a complete plan with counseling and psychosocial support.
- Suboxone sublingual film is given as a single daily dose.
- Suboxone sublingual film induction should start when clear signs of withdrawal are present, and it is given in divided doses at the start of treatment.
- Your prescriber should strongly consider recommending an opioid overdose reversal agent when Suboxone film is started or renewed.
Show 6 more strengths Show fewer strengths
Buprenorphine / Naloxone on the U.S. Market: Products, Makers and Brands
How Buprenorphine / Naloxone appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
29 companies list 102 Buprenorphine / Naloxone product records with the FDA, mostly as sublingual tablet, sublingual film; the earliest marketing or approval year on record is 2010. Brand names in the directory today include Suboxone and Zubsolv; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How Widely Buprenorphine / Naloxone Is Used (Medicaid Data)
How many Buprenorphine / Naloxone prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Buprenorphine / Naloxone prescribed? Of the 1,682 medications we measure, Buprenorphine / Naloxone ranks #21 by Medicaid prescriptions — more than 99% of them.
Utilization by Buprenorphine / Naloxone product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
buprenorphine 8 MG / naloxone 2 MG Sublingual Film Most dispensed
5 of 22 listed NDCs had Medicaid claims. RxNorm 1010604
buprenorphine 8 MG / naloxone 2 MG Sublingual Tablet
12 of 89 listed NDCs had Medicaid claims. RxNorm 351267
buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet
11 of 39 listed NDCs had Medicaid claims. RxNorm 351266
buprenorphine 12 MG / naloxone 3 MG Sublingual Film
5 of 20 listed NDCs had Medicaid claims. RxNorm 1307061
buprenorphine 4 MG / naloxone 1 MG Sublingual Film
5 of 18 listed NDCs had Medicaid claims. RxNorm 1307056
buprenorphine 2 MG / naloxone 0.5 MG Sublingual Film
5 of 22 listed NDCs had Medicaid claims. RxNorm 1010600
buprenorphine 5.7 MG / naloxone 1.4 MG Sublingual Tablet
1 of 2 listed NDCs had Medicaid claims. RxNorm 1431102
buprenorphine 8.6 MG / naloxone 2.1 MG Sublingual Tablet
1 of 2 listed NDCs had Medicaid claims. RxNorm 1597573
buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet
1 of 2 listed NDCs had Medicaid claims. RxNorm 1666338
buprenorphine 11.4 MG / naloxone 2.9 MG Sublingual Tablet
1 of 2 listed NDCs had Medicaid claims. RxNorm 1597568
buprenorphine 1.4 MG / naloxone 0.36 MG Sublingual Tablet
1 of 2 listed NDCs had Medicaid claims. RxNorm 1431076
buprenorphine 0.7 MG / naloxone 0.18 MG Sublingual Tablet
1 of 2 listed NDCs had Medicaid claims. RxNorm 1864412
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 49 of the 222 listed Buprenorphine / Naloxone NDCs had Medicaid claims.
Compare Buprenorphine / Naloxone Products
A representative set of FDA-listed product records for Buprenorphine / Naloxone — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Sublingual film | ||||
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg | Buccal, Sublingual | Alvogen Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 4 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 1 mg | Buccal, Sublingual | Alvogen Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Buccal, Sublingual | Alvogen Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 12 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 3 mg | Buccal, Sublingual | Alvogen Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE 0.5 mg | Buccal, Sublingual | Aveva Drug Delivery Systems Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 4 mg/1; NALOXONE HYDROCHLORIDE 1 mg | Buccal, Sublingual | Aveva Drug Delivery Systems Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE 2 mg | Buccal, Sublingual | Aveva Drug Delivery Systems Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 12 mg/1; NALOXONE HYDROCHLORIDE 3 mg | Buccal, Sublingual | Aveva Drug Delivery Systems Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE 0.5 mg | Buccal, Sublingual | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 4 mg/1; NALOXONE HYDROCHLORIDE 1 mg | Buccal, Sublingual | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE 2 mg | Buccal, Sublingual | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 12 mg/1; NALOXONE HYDROCHLORIDE 3 mg | Buccal, Sublingual | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE 0.5 mg | Buccal, Sublingual | Dr.Reddys Laboratories Inc | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 4 mg/1; NALOXONE 1 mg | Buccal, Sublingual | Dr.Reddys Laboratories Inc | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE 2 mg | Buccal, Sublingual | Dr.Reddys Laboratories Inc | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 12 mg/1; NALOXONE 3 mg | Buccal, Sublingual | Dr.Reddys Laboratories Inc | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE 0.5 mg | Buccal, Sublingual | Indivior Inc. | NDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 4 mg/1; NALOXONE HYDROCHLORIDE 1 mg | Buccal, Sublingual | Indivior Inc. | NDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE 2 mg | Buccal, Sublingual | Indivior Inc. | NDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 12 mg/1; NALOXONE HYDROCHLORIDE 3 mg | Buccal, Sublingual | Indivior Inc. | NDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE 0.5 mg | Buccal, Sublingual | Ingenus Pharmaceuticals, Llc | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 4 mg/1; NALOXONE HYDROCHLORIDE 1 mg | Buccal, Sublingual | Ingenus Pharmaceuticals, Llc | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE 2 mg | Buccal, Sublingual | Ingenus Pharmaceuticals, Llc | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 12 mg/1; NALOXONE HYDROCHLORIDE 3 mg | Buccal, Sublingual | Ingenus Pharmaceuticals, Llc | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg | Buccal, Sublingual | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 4 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 1 mg | Buccal, Sublingual | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Buccal, Sublingual | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 12 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 3 mg | Buccal, Sublingual | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE 0.5 mg | Buccal, Sublingual | Redpharm Drug | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg | Buccal, Sublingual | Redpharm Drug | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Buccal, Sublingual | Redpharm Drug | ANDA | View NDC → |
| 💊Sublingual tablet | ||||
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg | Sublingual | Accord Healthcare, Inc | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Sublingual | Accord Healthcare, Inc | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg | Sublingual | Actavis Pharma, Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Sublingual | Actavis Pharma, Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg | Sublingual | American Health Packaging | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Sublingual | American Health Packaging | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg | Sublingual | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Sublingual | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE 0.5 mg | Sublingual | Ascend Laboratories, LLC | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE 2 mg | Sublingual | Ascend Laboratories, LLC | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Sublingual | Asclemed USA, Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg | Sublingual | AvPAK | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Sublingual | AvPAK | ANDA | View NDC → |
| BUPRENORPHINE 2 mg/1; NALOXONE 0.5 mg | Sublingual | Bryant Ranch Prepack | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg | Sublingual | Bryant Ranch Prepack × 6 listings | ANDA | View NDC → |
| BUPRENORPHINE 8 mg/1; NALOXONE 2 mg | Sublingual | Bryant Ranch Prepack | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Sublingual | Bryant Ranch Prepack × 7 listings | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg | Sublingual | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Sublingual | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg | Sublingual | Clinical Solutions Wholesale, LLC × 3 listings | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Sublingual | Clinical Solutions Wholesale, LLC × 2 listings | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 0.7 mg/1; NALOXONE HYDROCHLORIDE 0.18 mg | Sublingual | Edenbridge Pharmaceuticals LLC. | NDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 1.4 mg/1; NALOXONE HYDROCHLORIDE 0.36 mg | Sublingual | Edenbridge Pharmaceuticals LLC. | NDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2.9 mg/1; NALOXONE HYDROCHLORIDE 0.71 mg | Sublingual | Edenbridge Pharmaceuticals LLC. | NDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 5.7 mg/1; NALOXONE HYDROCHLORIDE 1.4 mg | Sublingual | Edenbridge Pharmaceuticals LLC. | NDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8.6 mg/1; NALOXONE HYDROCHLORIDE 2.1 mg | Sublingual | Edenbridge Pharmaceuticals LLC. | NDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 11.4 mg/1; NALOXONE HYDROCHLORIDE 2.9 mg | Sublingual | Edenbridge Pharmaceuticals LLC. | NDA | View NDC → |
| NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg/1; BUPRENORPHINE HYDROCHLORIDE 2 mg | Sublingual | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Sublingual | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg | Sublingual | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Sublingual | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| BUPRENORPHINE 2 mg/1; NALOXONE 0.5 mg | Sublingual | Lannett Company, Inc. | ANDA | View NDC → |
| BUPRENORPHINE 8 mg/1; NALOXONE 2 mg | Sublingual | Lannett Company, Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg | Sublingual | Major Pharmaceuticals | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Sublingual | Major Pharmaceuticals | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 0.7 mg/1; NALOXONE HYDROCHLORIDE 0.18 mg | Sublingual | Orexo US, Inc. | NDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 1.4 mg/1; NALOXONE HYDROCHLORIDE 0.36 mg | Sublingual | Orexo US, Inc. | NDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2.9 mg/1; NALOXONE HYDROCHLORIDE 0.71 mg | Sublingual | Orexo US, Inc. | NDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 5.7 mg/1; NALOXONE HYDROCHLORIDE 1.4 mg | Sublingual | Orexo US, Inc. | NDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8.6 mg/1; NALOXONE HYDROCHLORIDE 2.1 mg | Sublingual | Orexo US, Inc. | NDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 11.4 mg/1; NALOXONE HYDROCHLORIDE 2.9 mg | Sublingual | Orexo US, Inc. | NDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE 0.5 mg | Sublingual | PAI Holdings, LLC dba PAI Pharma | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE 2 mg | Sublingual | PAI Holdings, LLC dba PAI Pharma | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Sublingual | Redpharm Drug × 2 listings | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg | Sublingual | Remedyrepack Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Sublingual | Remedyrepack Inc. × 2 listings | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg | Sublingual | Rhodes Pharmaceuticals LLC | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Sublingual | Rhodes Pharmaceuticals LLC | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg | Sublingual | SpecGx LLC | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Sublingual | SpecGx LLC | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg | Sublingual | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Sublingual | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg | Sublingual | Unit Dose Solutions, Inc. | ANDA | View NDC → |
| BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Sublingual | Unit Dose Solutions, Inc. × 2 listings | ANDA | View NDC → |
Showing 102 of 102 products — FDA National Drug Code Directory. See every product, package size and price: browse all 102 Buprenorphine / Naloxone NDCs →
Buprenorphine / Naloxone Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Buprenorphine / Naloxone — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Buprenorphine / Naloxone in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Buprenorphine / Naloxone FDA Approval History
How Buprenorphine / Naloxone went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Buprenorphine / Naloxone Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Buprenorphine / Naloxone recalls since July 2021.
✅No Buprenorphine / Naloxone recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Buprenorphine / Naloxone in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one exact combination of ingredients (MIN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. A different combination is a different concept with its own page.
- Dose forms
- 3
- Strengths
- 15
- Forms in current FDA listings
- 2 of 3
RxCUI 352364 -
Dose form (SCDF) Buccal FilmNo current FDA listing
RxCUI 1542389Its 3 strengths (SCD)-
buprenorphine 2.1 mg / naloxone 0.3 mg
RxCUI 1542390 -
buprenorphine 4.2 mg / naloxone 0.7 mg
RxCUI 1544851 -
buprenorphine 6.3 mg / naloxone 1 mg
RxCUI 1544854
-
buprenorphine 2.1 mg / naloxone 0.3 mg
-
Dose form (SCDF) Sublingual FilmIn current FDA listings
RxCUI 2269593Its 4 strengths (SCD)-
buprenorphine 2 mg / naloxone 0.5 mg
RxCUI 1010600 -
buprenorphine 4 mg / naloxone 1 mg
RxCUI 1307056 -
buprenorphine 8 mg / naloxone 2 mg
RxCUI 1010604 -
buprenorphine 12 mg / naloxone 3 mg
RxCUI 1307061
-
buprenorphine 2 mg / naloxone 0.5 mg
-
Dose form (SCDF) Sublingual TabletIn current FDA listings
RxCUI 378762Its 8 strengths (SCD)-
buprenorphine 0.7 mg / naloxone 0.18 mg
RxCUI 1864412 -
buprenorphine 1.4 mg / naloxone 0.36 mg
RxCUI 1431076 -
buprenorphine 2 mg / naloxone 0.5 mg
RxCUI 351266 -
buprenorphine 2.9 mg / naloxone 0.71 mg
RxCUI 1666338 -
buprenorphine 5.7 mg / naloxone 1.4 mg
RxCUI 1431102 -
buprenorphine 8 mg / naloxone 2 mg
RxCUI 351267 -
buprenorphine 8.6 mg / naloxone 2.1 mg
RxCUI 1597573 -
buprenorphine 11.4 mg / naloxone 2.9 mg
RxCUI 1597568
-
buprenorphine 0.7 mg / naloxone 0.18 mg
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Buprenorphine / Naloxone Supply and Shortage Status
Whether Buprenorphine / Naloxone is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
What Buprenorphine / Naloxone Costs Pharmacies (NADAC Benchmark)
What pharmacies pay to buy Buprenorphine / Naloxone: the national average from CMS’s weekly NADAC survey, as of Nov 18, 2026. It is the pharmacy’s cost, not your price at the counter.
How the Pharmacy Price Has Changed
Pick a form, the generic or the brand, and a strength to see how its price has changed since Nov 2023.
For the generic BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE 0.5 mg sublingual film, pharmacies paid an average of $1.33 each as of Nov 18, 2026, down 21% from $1.69 a year earlier.
- What pharmacies pay now
- $1.33
- each, as of Nov 18, 2026
- Last 4 weeks
- Down 3.8%
- from $1.39 on Oct 21, 2026
- Last 12 months
- Down 21%
- from $1.69 on Nov 19, 2025
- Lowest and highest since Nov 2023
- $1.24 to $2.26
- each
See the numbers, month by month
| Month | Pharmacy price |
|---|---|
| Nov 2026 | $1.33 |
| Oct 2026 | $1.39 |
| Sep 2026 | $1.39 |
| Aug 2026 | $1.38 |
| Jul 2026 | $1.31 |
| Jun 2026 | $1.28 |
| May 2026 | $1.30 |
| Apr 2026 | $1.31 |
| Mar 2026 | $1.29 |
| Feb 2026 | $1.34 |
| Jan 2026 | $1.33 |
| Dec 2025 | $1.56 |
| Nov 2025 | $1.69 |
| Oct 2025 | $1.91 |
| Sep 2025 | $1.90 |
| Aug 2025 | $1.92 |
| Jul 2025 | $1.87 |
| Jun 2025 | $1.86 |
| May 2025 | $1.89 |
| Apr 2025 | $1.89 |
| Mar 2025 | $1.88 |
| Feb 2025 | $1.79 |
| Jan 2025 | $1.61 |
| Dec 2024 | $1.61 |
| Nov 2024 | $1.24 |
| Oct 2024 | $1.88 |
| Sep 2024 | $2.04 |
| Aug 2024 | $2.03 |
| Jul 2024 | $1.38 |
| Jun 2024 | $1.89 |
| May 2024 | $1.41 |
| Apr 2024 | $1.41 |
| Mar 2024 | $2.18 |
| Feb 2024 | $2.06 |
| Jan 2024 | $2.14 |
| Dec 2023 | $2.16 |
| Nov 2023 | $2.17 |
See all 28 prices in a table
| Form | Strength | Version | What pharmacies pay | |
|---|---|---|---|---|
| Sublingual film · Buccal, Sublingual | BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE 0.5 mg | Generic | $1.33 each | NDC details & price history |
| Sublingual film · Buccal, Sublingual | BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE 0.5 mg | Generic | $1.33 each | NDC details & price history |
| Sublingual film · Buccal, Sublingual | BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE 0.5 mg | Suboxone (brand) | $4.78 each | NDC details & price history |
| Sublingual film · Buccal, Sublingual | BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg | Generic | $1.33 each | NDC details & price history |
| Sublingual film · Buccal, Sublingual | BUPRENORPHINE HYDROCHLORIDE 4 mg/1; NALOXONE 1 mg | Generic | $2.44 each | NDC details & price history |
| Sublingual film · Buccal, Sublingual | BUPRENORPHINE HYDROCHLORIDE 4 mg/1; NALOXONE HYDROCHLORIDE 1 mg | Generic | $2.44 each | NDC details & price history |
| Sublingual film · Buccal, Sublingual | BUPRENORPHINE HYDROCHLORIDE 4 mg/1; NALOXONE HYDROCHLORIDE 1 mg | Suboxone (brand) | $8.58 each | NDC details & price history |
| Sublingual film · Buccal, Sublingual | BUPRENORPHINE HYDROCHLORIDE 4 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 1 mg | Generic | $2.44 each | NDC details & price history |
| Sublingual film · Buccal, Sublingual | BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE 2 mg | Generic | $1.93 each | NDC details & price history |
| Sublingual film · Buccal, Sublingual | BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE 2 mg | Generic | $1.93 each | NDC details & price history |
| Sublingual film · Buccal, Sublingual | BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE 2 mg | Suboxone (brand) | $8.58 each | NDC details & price history |
| Sublingual film · Buccal, Sublingual | BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Generic | $1.93 each | NDC details & price history |
| Sublingual film · Buccal, Sublingual | BUPRENORPHINE HYDROCHLORIDE 12 mg/1; NALOXONE 3 mg | Generic | $4.13 each | NDC details & price history |
| Sublingual film · Buccal, Sublingual | BUPRENORPHINE HYDROCHLORIDE 12 mg/1; NALOXONE HYDROCHLORIDE 3 mg | Generic | $4.13 each | NDC details & price history |
| Sublingual film · Buccal, Sublingual | BUPRENORPHINE HYDROCHLORIDE 12 mg/1; NALOXONE HYDROCHLORIDE 3 mg | Suboxone (brand) | $17.16 each | NDC details & price history |
| Sublingual film · Buccal, Sublingual | BUPRENORPHINE HYDROCHLORIDE 12 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 3 mg | Generic | $4.13 each | NDC details & price history |
| Sublingual tablet · Sublingual | BUPRENORPHINE HYDROCHLORIDE 0.7 mg/1; NALOXONE HYDROCHLORIDE 0.18 mg | Zubsolv (brand) | $5.26 per tablet | NDC details & price history |
| Sublingual tablet · Sublingual | BUPRENORPHINE HYDROCHLORIDE 1.4 mg/1; NALOXONE HYDROCHLORIDE 0.36 mg | Zubsolv (brand) | $5.26 per tablet | NDC details & price history |
| Sublingual tablet · Sublingual | BUPRENORPHINE 2 mg/1; NALOXONE 0.5 mg | Generic | $0.539 per tablet | NDC details & price history |
| Sublingual tablet · Sublingual | BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE 0.5 mg | Generic | $0.539 per tablet | NDC details & price history |
| Sublingual tablet · Sublingual | BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 0.5 mg | Generic | $0.539 per tablet | NDC details & price history |
| Sublingual tablet · Sublingual | BUPRENORPHINE HYDROCHLORIDE 2.9 mg/1; NALOXONE HYDROCHLORIDE 0.71 mg | Zubsolv (brand) | $10.52 per tablet | NDC details & price history |
| Sublingual tablet · Sublingual | BUPRENORPHINE HYDROCHLORIDE 5.7 mg/1; NALOXONE HYDROCHLORIDE 1.4 mg | Zubsolv (brand) | $10.55 per tablet | NDC details & price history |
| Sublingual tablet · Sublingual | BUPRENORPHINE 8 mg/1; NALOXONE 2 mg | Generic | $0.735 per tablet | NDC details & price history |
| Sublingual tablet · Sublingual | BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE 2 mg | Generic | $0.735 per tablet | NDC details & price history |
| Sublingual tablet · Sublingual | BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg | Generic | $0.735 per tablet | NDC details & price history |
| Sublingual tablet · Sublingual | BUPRENORPHINE HYDROCHLORIDE 8.6 mg/1; NALOXONE HYDROCHLORIDE 2.1 mg | Zubsolv (brand) | $15.81 per tablet | NDC details & price history |
| Sublingual tablet · Sublingual | BUPRENORPHINE HYDROCHLORIDE 11.4 mg/1; NALOXONE HYDROCHLORIDE 2.9 mg | Zubsolv (brand) | $21.04 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC). Each row spans the package sizes CMS priced; the generic and the brand are priced separately.
Buprenorphine / Naloxone Brand Names
Buprenorphine / Naloxone has 3 brand names on record: Suboxone, Zubsolv and Bunavail. Suboxone and Zubsolv are in the FDA’s product directory today; Bunavail is not. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Buprenorphine / Naloxone: Manufacturers and Labelers
29 companies list Buprenorphine / Naloxone products with the FDA. By number of product records, the largest are Bryant Ranch Prepack, Camber Pharmaceuticals, Inc., Edenbridge Pharmaceuticals LLC.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
…and 5 more on the FDA NDC directory.
Sources for This Buprenorphine / Naloxone Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Orexo US, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →